PROTECTIVE EFFECT OF DMPC, DMPG, DMPC/DMPG, LYSOPG AND LYSOPC AGAINST DRUGS THAT CAUSE CHANNELOPATHIES
First Claim
1. A composition for preventing one or more cardiac channelopathies or conditions resulting from irregularities or alterations in cardiac patterns caused by an active agent or a drug in a human or animal subject comprising:
- an amount of a lysophosphatidylglycerol adapted for oral administration effective to reduce or prevent one or more cardiac channelopathies or conditions resulting from irregularities or alterations in cardiac patterns caused by the active agent or drug.
1 Assignment
0 Petitions
Accused Products
Abstract
The present invention includes compositions and methods for preventing one or more cardiac channelopathies or conditions resulting from irregularities or alterations in cardiac patterns caused by an active agent or a drug in a human or animal subject comprising: an amount of a lysophosphatidylglycerol adapted for oral administration effective to reduce or prevent one or more cardiac channelopathies or conditions resulting from irregularities or alterations in cardiac patterns caused by the active agent or drug.
12 Citations
40 Claims
-
1. A composition for preventing one or more cardiac channelopathies or conditions resulting from irregularities or alterations in cardiac patterns caused by an active agent or a drug in a human or animal subject comprising:
an amount of a lysophosphatidylglycerol adapted for oral administration effective to reduce or prevent one or more cardiac channelopathies or conditions resulting from irregularities or alterations in cardiac patterns caused by the active agent or drug. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11)
-
12. A composition for preventing or treating a diseases with an active agent or drug that causes one or more adverse reactions arising from administration of an active agent or drug in a human that causes at least one of cardiac channelopathies, IKr channel inhibition or QT prolongation comprising:
an amount of a lysophosphatidylglycerol with a basic structure; - View Dependent Claims (13, 14, 15, 16, 17, 18, 19, 20, 21, 22)
-
23. A method for preventing or treating one or more cardiac channelopathies, irregularities or alterations in cardiac patterns, IKr channel inhibition or QT prolongation, in a human or animal subject caused by an active agent or drug, wherein the active agent or drug are used to treat a disease in a human or animal subject comprising the steps of:
-
administering to the human or animal subject an amount of a lysophosphatidylglycerol adapted for oral administration effective to reduce or prevent one or cardiac channelopathies, irregularities or alterations in cardiac patterns, IKr channel inhibition, or QT prolongation caused by the active agent or drug; and an effective amount of the active agent or drug sufficient to treat the disease, wherein the orally provided lysophosphatidylglycerol reduces or eliminates the at least one cardiac channelopathies, irregularities or alterations in cardiac patterns, IKr channel inhibition or QT prolongation. - View Dependent Claims (24, 25, 26, 27, 28, 29, 30)
-
-
31. A method for preventing or treating one or more adverse reactions arising from administration of a therapeutically active agent or a drug in a human or animal subject comprising the steps of:
administering to the human or animal subject an amount of an amount of a lysophosphatidylglycerol with a basic structure;
-
32. A method for preventing or treating at least one of IKr channel inhibition or QT prolongation arising from administration of an active agent that causes a drug-induced channelopathy in a human or animal subject comprising the steps of:
-
identifying the human or animal subject in need of prevention or treatment of a disease treatable active agent that causes a drug-induced channelopathy; and an amount of a lysophosphatidylglycerol adapted for oral administration effective to reduce or prevent one or more cardiac channelopathies or conditions resulting from irregularities or alterations in cardiac patterns caused by the drug; and administering to the human or animal subject a therapeutically effective amount of an active agent that causes a drug-induced channelopathy, wherein the oral lysophosphatidylglycerol reduces or eliminates the channelopathy induced by the therapeutically active agent. - View Dependent Claims (33, 34, 35)
-
-
36. A method of evaluating a candidate drug, wherein the candidate drug causes a channelopathy, the method comprising:
-
(a) administering an amount of an oral lysophosphatidylglycerol and a candidate drug to a first subset of the patients, and a placebo to a second subset of the patients, wherein the oral liposome or liposome precursor is provided in an amount effective to reduce or prevent one or more cardiac channelopathies or conditions resulting from irregularities or alterations in cardiac patterns caused by the candidate drug; (b) measuring the level of channelopathy from the first and second set of patients; and (c) determining if the combination of the oral liposome or liposome precursors and the candidate drug reduce the drug-induced channelopathy that is statistically significant as compared to any reduction occurring in the subset of patients that took the placebo or to the known drug-induced channelopathy, wherein a statistically significant reduction indicates that the combination of the oral lysophosphatidylglycerol and the candidate drug is useful in treating a disease state while also reducing or eliminating the drug-induced channelopathy. - View Dependent Claims (37, 38, 39, 40)
-
Specification